PCSK9 conjugated liposomes for targeted delivery of paclitaxel to the cancer cell: A proof-of-concept study.

MLA

Charbe, Nitin Bharat, et al. “PCSK9 Conjugated Liposomes for Targeted Delivery of Paclitaxel to the Cancer Cell: A Proof-of-Concept Study.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 153, Sept. 2022, p. 113428. EBSCOhost, https://doi.org/10.1016/j.biopha.2022.113428.

APA

Charbe, N. B., Lagos, C. F., Ortiz, C. A. V., Tambuwala, M., Palakurthi, S. S., & Zacconi, F. C. (2022). PCSK9 conjugated liposomes for targeted delivery of paclitaxel to the cancer cell: A proof-of-concept study. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 153, 113428. https://doi.org/10.1016/j.biopha.2022.113428

Chicago

Charbe, Nitin Bharat, Carlos F Lagos, Cristian Andrés Vilos Ortiz, Murtaza Tambuwala, Sushesh Srivatsa Palakurthi, and Flavia C Zacconi. 2022. “PCSK9 Conjugated Liposomes for Targeted Delivery of Paclitaxel to the Cancer Cell: A Proof-of-Concept Study.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 153 (September): 113428. doi:10.1016/j.biopha.2022.113428.